Different risk factors for bleeding and discontinuation between dabigatran and rivaroxaban

Journal of Cardiology

Volumn 68, Issue 2, 2016, Pages 156-160

  Nishino, Masami ^a   Okamoto, Naotaka ^a   Tanaka, Akihiro ^a   Mori, Naoki ^a   Hara, Masahiko ^b   Yano, Masamichi ^a   Makino, Nobuhiko ^a   Egami, Yasuyuki ^a   Shutta, Ryu ^a   Tanouchi, Jun ^a  

^a OSAKA ROSAI HOSPITAL   (Japan)

^b OSAKA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Atrial fibrillation; Bleeding; Dabigatran; Non vitamin K oral antagonists; Rivaroxaban

Indexed keywords

ANTIVITAMIN K; DABIGATRAN; HEMOGLOBIN; RIVAROXABAN; ANTITHROMBIN; ANTITHROMBOCYTIC AGENT;

AGED; ARTICLE; ATRIAL FIBRILLATION; BLEEDING; CHADS2 SCORE; CORRELATIONAL STUDY; CREATININE CLEARANCE; DEMOGRAPHY; DRUG USE; DRUG WITHDRAWAL; DYSPEPSIA; EPISTAXIS; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INCIDENCE; LABORATORY TEST; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PROTHROMBIN TIME; RISK FACTOR; SIDE EFFECT; SUBCUTANEOUS BLEEDING; CHEMICALLY INDUCED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG SUBSTITUTION; HEMORRHAGE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPENSITY SCORE; TREATMENT OUTCOME; TREATMENT WITHDRAWAL; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; DABIGATRAN; DRUG SUBSTITUTION; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEMORRHAGE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PLATELET AGGREGATION INHIBITORS; PROPENSITY SCORE; RISK FACTORS; RIVAROXABAN; TREATMENT OUTCOME; WITHHOLDING TREATMENT;

EID: 84945943570     PISSN: 09145087     EISSN: 18764738     Source Type: Journal    
DOI: 10.1016/j.jjcc.2015.08.019     Document Type: Article

References (23)

1. [1] Pisters, R., Lane, D.A., Nieuwlaat, R., de Vos, C.B., Crijns, H.J., Lip, G.Y., A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest 138 (2010), 1093–1100.
2. [2] Kawai, H., Watanabe, E., Yamamoto, M., Harigaya, H., Sano, K., Takatsu, H., Muramatsu, T., Naruse, H., Sobue, Y., Motoyama, S., Sarai, M., Takahashi, H., Arakawa, T., Kan, S., Sugiura, A., et al. Major bleeding complications related to combined antithrombotic therapy in atrial fibrillation patients 12 months after coronary artery stenting. J Cardiol 65 (2015), 197–202.
3. [3] Takarada, K., Sato, M., Goto, M., Saito, A., Ikeda, Y., Fujita, S., Fuse, K., Takahashi, M., Oguro, T., Matsushita, H., Kitazawa, H., Okabe, M., Abe, H., Toba, K., Yamashina, A., et al. Long-term PT-INR levels and the clinical events in the patients with non-valvular atrial fibrillation: a special reference to low-intensity warfarin therapy. J Cardiol 64 (2014), 127–132.
4. [4] Connolly, S.J., Ezekowitz, M.D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P.A., Themeles, E., Varrone, J., Wang, S., Alings, M., Xavier, D., Zhu, J., Diaz, R., et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361 (2009), 1139–1151.
5. [5] Poulsen, B.K., Grove, E.L., Husted, S.E., New oral anticoagulants: a review of the literature with particular emphasis on patients with impaired renal function. Drugs 72 (2012), 1739–1753.
6. [6] Liew, A., Eikelboom, J.W., O'Donnell, M., Hart, R.G., Assessment of anticoagulation intensity and management of bleeding with old and new oral anticoagulants. Can J Cardiol 29 (2013), S34–S44.
7. [7] Patel, M.R., Mahaffey, K.W., Garg, J., Pan, G., Singer, D.E., Hacke, W., Breithardt, G., Halperin, J.L., Hankey, G.J., Piccini, J.P., Becker, R.C., Nessel, C.C., Paolini, J.F., Berkowitz, S.D., Fox, K.A., et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 365 (2011), 883–891.
8. [8] Lip, G.Y., Larsen, T.B., Skjoth, F., Rasmussen, L.H., Indirect comparisons of new oral anticoagulant drugs for efficacy and safety when used for stroke prevention in atrial fibrillation. J Am Coll Cardiol 60 (2012), 738–746.
9. [9] Gage, B.F., Waterman, A.D., Shannon, W., Boechler, M., Rich, M.W., Radford, M.J., Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 285 (2001), 2864–2870.
10. [10] Cockcroft, D.W., Gault, M.H., Prediction of creatinine clearance from serum creatinine. Nephron 16 (1976), 31–41.
11. [11] Schulman, S., Kearon, C., Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3 (2005), 692–694.
12. [12] Austin, P.C., The performance of different propensity score methods for estimating marginal hazard ratios. Stat Med 32 (2013), 2837–2849.
13. [13] Suzuki, S., Sagara, K., Otsuka, T., Kano, H., Matsuno, S., Takai, H., Uejima, T., Oikawa, Y., Koike, A., Nagashima, K., Kirigaya, H., Yajima, J., Tanabe, H., Sawada, H., Aizawa, T., et al. Blue letter effects: changes in physicians’ attitudes toward dabigatran after a safety advisory in a specialized hospital for cardiovascular care in Japan. J Cardiol 62 (2013), 366–373.
14. [14] Beyer-Westendorf, J., Ebertz, F., Förster, K., Gelbricht, V., Michalski, F., Köhler, C., Werth, S., Endig, H., Pannach, S., Tittl, L., Sahin, K., Daschkow, K., Weiss, N., Effectiveness and safety of dabigatran therapy in daily-care patients with atrial fibrillation. Results from the Dresden NOAC Registry. Thromb Haemost, 113, 2015.
15. [15] Ho, M.H., Ho, C.W., Cheung, E., Chan, P.H., Hai, J.J., Chan, K.H., Chan, E.W., Leung, G.K., Tse, H.F., Siu, C.W., Continuation of dabigatran therapy in real-world practice in Hong Kong. PLOS ONE, 9, 2014, e101245, 10.1371/journal.pone.0101245 eCollection 2014.
16. [16] Laliberte, F., Nelson, W.W., Lefebvre, P., Schein, J.R., Rondeau-Leclaire, J., Duh, M.S., Impact of daily dosing frequency on adherence to chronic medications among nonvalvular atrial fibrillation patients. Adv Ther 29 (2012), 675–690.
17. [17] Sherid, M., Sifuentes, H., Sulaiman, S., Samo, S., Husein, H., Tupper, R., Thiruvaiyaru, D., Spurr, C., Sridhar, S., Risk of gastrointestinal bleeding with dabigatran: a head-to-head comparative study with rivaroxaban. Digestion 90 (2014), 137–146.
18. [18] Hernandez, I., Baik, S.H., Pinera, A., Zhang, Y., Risk of bleeding with dabigatran in atrial fibrillation. JAMA Intern Med 175 (2015), 18–24.
19. [19] Cuker, A., Siegal, D.M., Crowther, M.A., Garcia, D.A., Laboratory measurement of the anticoagulant activity of the non-vitamin K oral anticoagulants. J Am Coll Cardiol 64 (2014), 1128–1139.
20. [20] Ogawa, S., Koretsune, Y., Yasaka, M., Aizawa, Y., Atarashi, H., Inoue, H., Kamakura, S., Kumagai, K., Mitamura, H., Okumura, K., Sugi, K., Yamashita, T., Antithrombotic therapy in atrial fibrillation: evaluation and positioning of new oral anticoagulant agents. Circ J 75 (2011), 1539–1547.
21. [21] Mega, J.L., Braunwald, E., Wiviott, S.D., Bassand, J.P., Bhatt, D.L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K.A., Goto, S., Murphy, S.A., Plotnikov, A.N., Schneider, D., Sun, X., et al. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 366 (2012), 9–19.
22. [22] Oldgren, J., Budaj, A., Granger, C.B., Khder, Y., Roberts, J., Siegbahn, A., Tijssen, J.G., Van de Werf, F., Wallentin, L., RE-DEEM Investigators. Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial. Eur Heart J 32 (2011), 2781–2789.
23. [23] Davies, M.J., Thomas, A., Thrombosis and acute coronary-artery lesions in sudden cardiac ischemic death. N Engl J Med 310 (1984), 1137–1140.